Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index
TB Kelleher, SH Mehta, R Bhaskar, M Sulkowski… - Journal of …, 2005 - Elsevier
BACKGROUND/AIMS: To examine if serum fibrosis biomarkers could accurately identify the
stage of liver disease amongst hepatitis C (HCV) and HIV co-infected patients. METHODS …
stage of liver disease amongst hepatitis C (HCV) and HIV co-infected patients. METHODS …
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results
RL Murphy, I Sanne, P Cahn, P Phanuphak, L Percival… - Aids, 2003 - journals.lww.com
Objective: To compare the efficiency and safety of atazanavir and nelfinavir in antiretroviral-
naive patients. Design: Randomization to atazanavir 400 mg or 600 mg once daily; nelfinavir …
naive patients. Design: Randomization to atazanavir 400 mg or 600 mg once daily; nelfinavir …
Atazanavir—a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials
PE Cahn, JM Gatell, K Squires… - Journal of the …, 2004 - journals.sagepub.com
Protease inhibitor (PI) treatment can result in dyslipidemia in a significant proportion of
patients. Atazanavir (ATV) is a once-daily PI that has not been associated with clinically …
patients. Atazanavir (ATV) is a once-daily PI that has not been associated with clinically …
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of …
Background Regulatory qualification of a biomarker for a defined context of use provides
scientifically robust assurances to sponsors and regulators that accelerate appropriate …
scientifically robust assurances to sponsors and regulators that accelerate appropriate …
[BOOK][B] Smith, Currie and Hancock's common sense construction law: A practical guide for the construction professional
TJ Kelleher Jr, JM Mastin, RG Robey - 2014 - books.google.com
Cut through the legalese to truly understand construction law Smith, Currie & Hancock's
Common Sense Construction Law is a guide for non-lawyers, presenting a practical …
Common Sense Construction Law is a guide for non-lawyers, presenting a practical …
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir
R Wood, P Phanuphak, P Cahn… - JAIDS Journal of …, 2004 - journals.lww.com
The purpose of the study was to determine long-term efficacy, safety, and tolerability of
atazanavir plus stavudine/lamivudine in 346 HIV-infected patients previously treated with …
atazanavir plus stavudine/lamivudine in 346 HIV-infected patients previously treated with …
Advanced hepatocellular carcinoma associated with cystic fibrosis
T Kelleher, M Staunton, S O'Mahony… - European journal of …, 2005 - journals.lww.com
Advances in the treatment of the respiratory complications of cystic fibrosis, including the
availability of lung transplantation have led to a greater awareness of the manifestations of …
availability of lung transplantation have led to a greater awareness of the manifestations of …
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled …
H Roché, P Conte, EA Perez, JA Sparano, B Xu… - Breast cancer research …, 2011 - Springer
Patients with metastatic breast cancer (MBC) previously treated with anthracyclines and
taxanes often have decreased performance status secondary to extensive tumor …
taxanes often have decreased performance status secondary to extensive tumor …
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine
T Kelleher, A Cross, L Dunkle - Clinical therapeutics, 1999 - Elsevier
Peripheral neuropathy has been recognized as a dose-limiting adverse effect in Phase I
studies of didanosine (ddI) therapy for HIV infection. To study the effect of the currently …
studies of didanosine (ddI) therapy for HIV infection. To study the effect of the currently …
The effects of the Roche AMPLICOR HIV-1 MONITOR® UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of …
M Giordano, T Kelleher, RJ Colonno, A Lazzarin… - Journal of clinical …, 2006 - Elsevier
BACKGROUND: Because there are limited head-to-head data comparing antiretroviral
combinations, physicians are tempted to rely on cross-trial comparisons to evaluate the …
combinations, physicians are tempted to rely on cross-trial comparisons to evaluate the …